Key Highlights

  • Jin Medical International (NASDAQ:ZJYL) traded at USD 3.13 on November 12, 2026, a 36.35% decrease, on about 85,680 shares, equating to a Market Value close to USD 494.36 million.
  • No company announcement surfaced for November 10 to 12, and the 14.6% jump on November 9 likewise lacked any news behind it.
  • Revenue for the six months ended March 31, 2026 declined 9.7% to USD 8.9 million, and the company posted a net loss of USD 0.2 million.
  • Despite the drop, the stock trades near 20.86 times trailing diluted Earnings of USD 0.15 per share.

A Reversal Lacking a Disclosed Trigger

Jin Medical International (NASDAQ:ZJYL) makes and sells wheelchairs, walking aids and other mobility and rehabilitation gear from its Chuzhou plant in China, distributing through partners in China, Japan and elsewhere. On November 12 the shares fell 36.35% to USD 3.13 on about 85,680 shares, far below normal volume. Checks for November 10 to 12 found no announcement, filing or contract news. The slide came after an early-November rally, which included a 14.6% gain on November 9 that lifted the stock to USD 3.85 intraday on light volume, again without any company news. The 50-day average near that time was about USD 2.14, so the November advance had carried the shares well above their recent range, and the stock had not traded near the early-November peak before that. Sharp reversals after unexplained rallies are common in thinly traded small caps, though that reading is an interpretation, not a verified cause. With no fresh announcement backing the higher price, buyers pulled back and the gains reversed in one session.

Fundamentals Fail to Justify the Valuation

Recent results describe a company shrinking slightly and roughly at break-even. For the six months ended March 31, 2026, Revenue dropped 9.7% to USD 8.9 million from USD 9.9 million, wheelchair sales made up USD 7.1 million, gross Margin rose to 26.9% from 24.3%, and the net loss totaled USD 0.2 million, or USD 0.01 per share. The Balance Sheet is sturdy, holding USD 9.1 million in cash and USD 21.0 million in short-term investments. The screen lists trailing diluted earnings of USD 0.15 per share, down 34.59% year over year, and a price-to-earnings ratio near 20.86. A market value around USD 494.36 million is large compared with annualized revenue below USD 20 million, leaving the shares prone to sharp moves when trading interest wanes. Anyone comparing market value with the revenue base should be cautious about the valuation until new results show whether margins and sales can improve together.

Capacity Expansion and Key Watch Items

The company executed a 1-for-20 share combination in March 2026 and recovered Nasdaq minimum bid compliance in April. In January it announced that its Chuzhou Facility received clearance for Class I medical device manufacturing, targeting full capacity by the end of April 2026 and annual output of 200,000 units. Long-term Demand for mobility aids is backed by aging populations in China and Japan, its primary markets. Investors should look for full-year results covering the period ending September 30, any update on how much of the new capacity is in use, and whether revenue resumes growth. Any update that clarifies whether the Chuzhou expansion is generating orders would help investors judge the share price. Until fresh operating data appears, the share price will likely track trading flows more than underlying fundamentals.

Where Things Stand

Jin Medical International (NASDAQ:ZJYL) dropped 36.35% to USD 3.13 on November 12, 2026, with no company news found, reversing an early-November run-up. Revenue fell 9.7% in the most recent half year, and the shares still trade near 20.86 times trailing earnings, so updated results and capacity use will be decisive.